Literature DB >> 28612957

Impact of end-stage renal disease in children on their parents.

Hee Sun Baek1, Ki-Soo Park2, Il Soo Ha3, Hee Gyung Kang3, Hae Il Cheong3, Young Seo Park4, Joo Hoon Lee4, Hee Yeon Cho5, Min Hyun Cho1.   

Abstract

AIM: This study was designed to investigate the impact of paediatric end-stage renal disease (ESRD) on parents, based on the PedsQL Family Impact Module (FIM), and the relationship to the quality of life (QOL) of paediatric ESRD patients measured by PedsQL 3.0 ESRD module.
METHODS: We performed a cross-sectional study using Korean translations of the PedsQL FIM and the PedsQL 3.0 ESRD module. In all, 79 patients were enrolled, including 47 children receiving dialysis and 32 children who underwent renal transplant.
RESULTS: FIM scores, analyzed for every category according to treatment modality, were significantly lower in haemodialysis (HD) than in peritoneal dialysis (PD) or renal transplant patients. Mother's age, duration since diagnosis of ESRD and the existence of comorbidity were variables to have significant effects on FIM scores. The correlation between total FIM and QOL scores of paediatric patients were significant, in both parent-proxy and child-self report.
CONCLUSIONS: The PedsQL FIM appears to be a useful tool for the assessment of family impact on children with ESRD. Further prospective studies focused on the QOL of parents and caregivers should be performed with the goal of improving clinical outcomes for paediatric ESRD patients.
© 2017 Asian Pacific Society of Nephrology.

Entities:  

Keywords:  children; end stage renal disease; family; parents; quality of life

Mesh:

Year:  2018        PMID: 28612957     DOI: 10.1111/nep.13083

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  1 in total

1.  Comparison of quality of life in children undergoing peritoneal dialysis versus hemodialysis.

Authors:  Ola A Alhusaini; Lamis A Wayyani; Hadeer E Dafterdar; Mariyah M Gamlo; Zainab A Alkhayat; Abeer S Alghamdi; Osama Y Safdar
Journal:  Saudi Med J       Date:  2019-08       Impact factor: 1.484

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.